


**WHAT IS CLAIMED IS:**

1. A compound of the Formula (I):



(I)

5 wherein:

R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, trihalomethane-sulfonamido, carbonyl, C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, amino and -NR<sup>11</sup>R<sup>12</sup> where R<sup>11</sup> and R<sup>12</sup> are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, acetyl, sulfonyl, and trifluoromethanesulfonyl, or R<sup>11</sup> and R<sup>12</sup>, together with the nitrogen atom to which they are attached, combine to form a five- or six-member heteroalicyclic ring provided that at least two of R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are hydrogen; or

R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup> may combine to form a six-membered aryl ring, a methylenedioxy group or an ethylenedioxy group;

20 R<sup>7</sup> is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, carbonyl, acetyl, C-amido, C-thioamido, amidino, C-carboxy, O-carboxy, sulfonyl and trihalomethane-sulfonyl;

R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy,

alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, carbonyl, C-carboxy, O-carboxy, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, amino and -NR<sup>11</sup>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> are as defined above;

5 R<sup>1</sup> is hydrogen or alkyl; and

R<sup>3</sup> and R<sup>4</sup> are independently alkyl or combine to form a heteroalicyclic ring or a heteroaryl ring provided that the heteroalicyclic ring is not piperidin-1-yl or morpholin-4-yl; or

a pharmaceutically acceptable salt thereof.

10

2. The compound of Claim 1, wherein R<sup>3</sup> and R<sup>4</sup> combine to form a heteroalicyclic ring.

15 3. The compound of Claim 1, wherein R<sup>3</sup> and R<sup>4</sup> combine to form pyrrolidin-1-yl, 2-hydroxymethylpyrrolidin-1-yl, 2-carboxypyrrolidin-1-yl, or 4-methylpiperazin-1-yl.

4. The compound of Claim 1, wherein R<sup>3</sup> and R<sup>4</sup> are independently lower alkyl optionally substituted with a hydroxy group.

20

5. The compound of Claim 1, wherein R<sup>3</sup> and R<sup>4</sup> are 2-hydroxyethyl.

6. The compound of any one of Claims 2, 3, 4, or 5 wherein R<sup>1</sup> and R<sup>7</sup> are hydrogen.

25

7. The compound of Claim 1, wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>9</sup> are hydrogen, R<sup>8</sup> and R<sup>10</sup> are unsubstituted lower alkyl; and R<sup>3</sup> and R<sup>4</sup> combine to form a heteroalicyclic ring.

30

8. The compound of Claim 7, wherein R<sup>8</sup> and R<sup>10</sup> are methyl and R<sup>1</sup> is hydrogen.

9. The compound of Claim 7, wherein R<sup>8</sup> and R<sup>10</sup> are methyl, R<sup>1</sup> is hydrogen, and R<sup>3</sup> and R<sup>4</sup> combine to form 2-hydroxymethyl-pyrrolidin-1-yl or 2-carboxy-pyrrolidin-1-yl.

5


10. The compound of Claim 1, wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> are hydrogen and R<sup>8</sup> and R<sup>10</sup> are unsubstituted lower alkyl.

11. The compound of Claim 10, wherein R<sup>9</sup> is C-amido or lower alkyl  
10 substituted with carboxy and R<sup>1</sup> and R<sup>7</sup> are hydrogen.

12. The compound of Claim 11, wherein R<sup>8</sup> and R<sup>10</sup> are methyl and R<sup>3</sup> and R<sup>4</sup> combine to form a heteroalicyclic ring.


15 13. The compound of Claim 12, wherein R<sup>3</sup> and R<sup>4</sup> combine to form a  
pyrrolidin-1-yl.

14. The compound of Claim 1, wherein the compound is



20

15. The compound of Claim 1, wherein the compound is



16. The compound of Claim 1, wherein R<sup>3</sup> and R<sup>4</sup> combine to form a  
25 heteroaryl ring.

17. The compound of Claim 1, wherein R<sup>3</sup> and R<sup>4</sup> combine to form a pyridin-1-yl ring.

5 18. The compound of Claim 17, wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> are hydrogen and R<sup>8</sup> and R<sup>10</sup> are unsubstituted lower alkyl.

19. The compound of Claim 18, wherein R<sup>8</sup> and R<sup>10</sup> are methyl.

10 20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of Claim 1.

15 21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of Claim 15.

22. The pharmaceutical composition of Claim 20, wherein said composition is administered parenterally.

20 23. The pharmaceutical composition of Claim 21, wherein said composition is administered parenterally.

24. A method of treating a human having a disease capable of treatment by administration of a protein kinase inhibitor, comprising administration to that human a therapeutically effective amount of a compound of Claim 1.

25 25. A method of treating a human having a disease capable of treatment by administration of a protein kinase inhibitor, comprising administration to that human a therapeutically effective amount of a compound of Claim 15.

26. The method of Claim 25, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases and infectious diseases.

5 27. The method of Claim 26, wherein the cancer is selected from the group consisting of colorectal cancer, Kaposi's sarcoma and lung cancer.


28. The method of Claim 26, wherein the blood vessel proliferative disorder is selected from the group consisting of arthritis and restenosis.

10 29. The method of Claim 28, wherein the fibrotic disorder is selected from the group consisting of hepatic cirrhosis and atherosclerosis.

15 30. The method of Claim 28, wherein the mesangial cell proliferative disorder is selected from the group consisting of glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection and glomerulopathies.

20 31. The method of Claim 28, wherein the metabolic disease is selected from the group consisting of psoriasis, diabetes mellitus, wound healing, inflammation and neurodegenerative diseases.

32. A process of preparing a compound of Formula (I) comprising reacting a compound of Formula (II)



(II)

with an amine of formula  $-NR^3R^4$  in the presence of an aldehyde of formula  $R^1CHO$  where  $R^1$ ,  $R^3$  and  $R^4$  are as defined in Claim 1 above.

5        33. The process of claim 32, further comprising modifying any of the  $R^3-R^{10}$  groups of the compound of Formula (II).

34. The process of claim 32, further comprising preparing an acid addition salt of the compound of Formula (II).

10      35. The process of Claim 31, wherein the aldehyde is formaldehyde and the amine is pyrrolidine.

15      36. The process of Claim 31, wherein  $R^3-R^7$  and  $R^9$  are hydrogen and  $R^8$  and  $R^{10}$  are methyl.